Advertisement
Canada markets close in 3 hours 52 minutes
  • S&P/TSX

    22,340.63
    +81.16 (+0.36%)
     
  • S&P 500

    5,195.23
    +14.49 (+0.28%)
     
  • DOW

    38,906.90
    +54.63 (+0.14%)
     
  • CAD/USD

    0.7294
    -0.0027 (-0.37%)
     
  • CRUDE OIL

    78.38
    -0.10 (-0.13%)
     
  • Bitcoin CAD

    87,523.99
    +196.36 (+0.22%)
     
  • CMC Crypto 200

    1,321.44
    -43.68 (-3.20%)
     
  • GOLD FUTURES

    2,322.70
    -8.50 (-0.36%)
     
  • RUSSELL 2000

    2,076.97
    +16.30 (+0.79%)
     
  • 10-Yr Bond

    4.4250
    -0.0640 (-1.43%)
     
  • NASDAQ

    16,386.50
    +37.26 (+0.23%)
     
  • VOLATILITY

    13.47
    -0.02 (-0.15%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6769
    -0.0023 (-0.34%)
     

Why Gilead Sciences Stock Was a 5% Winner Today

Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company had some good news to impart about an important cancer drug. Gilead announced that morning that its breast cancer treatment Trodelvy recorded "statistically significant and clinically meaningful" results in a phase 3 clinical trial.